Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where K Salmela is active.

Publication


Featured researches published by K Salmela.


The Lancet | 2002

Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation

Lisa Moberg; H. Johansson; Agneta Lukinius; Christian Berne; Aksel Foss; Ragnar Källén; Ø Østraat; K Salmela; Annika Tibell; Gunnar Tufveson; Graciela Elgue; K Nilsson Ekdahl; Olle Korsgren; Bo Nilsson

BACKGROUND Intraportal transplantation of pancreatic islets offers improved glycaemic control and insulin independence in type 1 diabetes mellitus, but intraportal thrombosis remains a possible complication. The thrombotic reaction may explain why graft loss occurs and islets from more than one donor are needed, since contact between human islets and ABO-compatible blood in vitro triggers a thrombotic reaction that damages the islets. We investigated the possible mechanism and treatment of such thrombotic reactions. METHODS Coagulation activation and islet damage were monitored in four patients undergoing clinical islet transplantation according to a modified Edmonton protocol. Expression of tissue factor (TF) in the islet preparations was investigated by immunohistochemistry, immunoprecipitation, electron microscopy, and RT-PCR. To assess TF activity in purified islets, human islets were mixed with non-anticoagulated ABO-compatible blood in tubing loops coated with heparin. FINDINGS Coagulation activation and subsequent release of insulin were found consistently after clinical islet transplantation, even in the absence of signs of intraportal thrombosis. The endocrine, but not the exocrine, cells of the pancreas were found to synthesise and secrete active TF. The clotting reaction triggered by pancreatic islets in vitro could be abrogated by blocking the active site of TF with specific antibodies or site-inactivated factor VIIa, a candidate drug for inhibition of TF activity in vivo. INTERPRETATION Blockade of TF represents a new therapeutic approach that might increase the success of islet transplantation in patients with type 1 diabetes, in terms of both the risk of intraportal thrombosis and the need for islets from more than one donor.


Diabetologia | 1998

Implantation of standardized beta-cell grafts in a liver segment of IDDM patients: graft and recipient characteristics in two cases of insulin-independence under maintenance immunosuppression for prior kidney graft

Bart Keymeulen; Zhidong Ling; Frans K. Gorus; G. Delvaux; Luc Bouwens; Annick Y. Grupping; C. Hendrieckx; M. Pipeleers-Marichal; C. Van Schravendijk; K Salmela; D. Pipeleers

Summary Islet allografts in insulin-dependent diabetic (IDDM) patients exhibit variable survival lengths and low rates of insulin-independence despite treatment with anti-T-cell antibodies and maintenance immunosuppression. Use of poorly characterized freshly isolated preparations makes it difficult to determine whether failures are caused by variations in donor tissue. This study assesses survival of standardized beta-cell allografts in C-peptide negative IDDM patients on maintenance immunosuppression following kidney transplantation and without receiving anti-T-cell antibodies or additional immunosuppression. Human islets were isolated from pancreatic segments after maximal 20 h cold-preservation. During culture, preparations were selected according to quality control tests and combined with grafts with standardized cell composition (≥ 50 % beta cells), viability ( ≥ 90 % ), total beta-cell number (1 to 2 · 106/kg body weight) and insulin-producing capacity (2 to 4 nmol · graft–1· h–1). Grafts were injected in a liver segment through the repermeabilized umbilical vein. After 2 weeks C-peptide positivity, four out of seven recipients became C-peptide negative; two of them were initially GAD65-antibody positive and exhibited a rise in titre during graft destruction. The other three patients remained C-peptide positive for more than 1 year, two of them becoming insulin-independent with near-normal fasting glycaemia and HbA1 c; they remained GAD65- and islet cell antibody negative. The three patients with surviving grafts presented a history of anti-thymocyte globulin therapy at kidney transplantation. Long-term surviving grafts increased C-peptide release following intravenous glucagon or oral glucose but not following intravenous glucose. Thus, cultured human beta-cells can survive for more than 1 year in IDDM patients on maintenance anti-rejection therapy for a prior kidney graft and without the need for an increased immunosuppression at the time of implantation. The use of functionally standardized beta-cell grafts helps to identify recipient and graft factors which influence their survival and metabolic effects. Insulin-independence can be achieved by injection of 1.5 million beta-cells per kg body weight in a liver segment. These beta-cell implants respond well to adenylcyclase activators but poorly to glucose. [Diabetologia (1998) 41: 452–459]


Transplantation | 2003

Nicotinamide inhibits tissue factor expression in isolated human pancreatic islets: Implications for clinical islet transplantation

Lisa Moberg; Annika Olsson; Christian Berne; Marie Felldin; Aksel Foss; Ragnar Källén; K Salmela; Annika Tibell; Gunnar Tufveson; Bo Nilsson; Olle Korsgren

Background. Islet-produced tissue factor (TF) triggers an adverse clotting reaction, the instant blood-mediated inflammatory reaction (IBMIR), providing a likely explanation for the need of tissue from multiple donors in clinical islet transplantation. In this study, the authors investigated whether compounds previously shown to affect TF and macrophage chemoattractant protein (MCP)-1 expression in monocytes and endothelial cells have the same effect in human islet cells. Methods. Islets were cultured in the presence of l-arginine, cyclosporine A, enalapril, or nicotinamide for 48 hr, after which the TF content and MCP-1 expression were assessed. The effect of nicotinamide on IBMIR was evaluated by exposing the treated islets to fresh human ABO-compatible blood in an in vitro loop model. Results. Nicotinamide was the only compound that significantly reduced both TF and MCP-1. This reduction was dose-dependent. The level of MCP-1 was strongly correlated with TF expression (r2=0.98). In addition, the level of TF was also correlated with the ability of the islets to initiate IBMIR (r2=0.94). Conclusions. TF and MCP-1 expression in human islets can be decreased by adding nicotinamide to the culture medium. These observations indicate that the adverse effects of IBMIR in clinical islet transplantation could be reduced without endangering the recipient using antithrombotic drugs.


Transplantation | 2007

No beneficial effect of two-layer storage compared with UW-storage on human islet isolation and transplantation

José Caballero-Corbalán; Torsten Eich; Torbjoern Lundgren; Aksel Foss; Marie Felldin; Ragnar Källén; K Salmela; Annika Tibell; Gunnar Tufveson; Olle Korsgren; Daniel Brandhorst

Background. Shipment of pancreata between distant centers is frequently associated with prolonged cold ischemia time (CIT) that leads to poorer outcomes for islet transplantation. Clinical pilot trials have indicated that oxygenation of explanted human pancreata utilizing the two-layer method (TLM) allows the use of marginal donor pancreata for islet transplantation. The present study aimed to clarify whether TLM enhances the ischemic tolerance of human pancreata. Methods. We analyzed retrospectively the outcome of 200 human islet isolations performed after TLM preservation or storage in University of Wisconsin solution (UWS). Results. Donor characteristics and digestion parameters did not vary significantly between TLM-preserved and UWS-stored pancreata. No differences were observed between experimental groups with regard to islet yield, purity, or dynamic glucose stimulation index after either short or prolonged CIT. However, CIT and stimulation index were negatively correlated in each experimental group. The isolation outcome in donors aged ≥60 years was not increased after TLM preservation when compared to UWS storage. No effect was observed regarding islet posttransplant function in recipients with established kidney grafts. Conclusions. The present study suggests that the ischemic tolerance of human pancreata cannot be extended by TLM preservation. In addition, TLM does not seem to improve the isolation outcome for pancreata from elderly donors.


Cell Transplantation | 2010

Large-Scale Comparison of Liberase HI and Collagenase NB1 Utilized for Human Islet Isolation

H Brandhorst; Andrew S. Friberg; Bo Nilsson; Helene H. Andersson; M Felldin; Aksel Foss; K Salmela; Annika Tibell; Gunnar Tufveson; Olle Korsgren; Daniel Brandhorst

For more than a decade Liberase HI was commonly used as the standard enzyme blend for clinical human islet isolation until enforced replacement by collagenase NB1 (NB1). This change resulted initially in a reduction in islet isolation outcome and transplant activities worldwide. This retrospective study was initiated to compare the efficiency of NB1 premium grade with Liberase in 197 human islet isolations. All pancreata were processed between January 2006 and June 2008 utilizing the same procedures for isolation and quality assessment except the administration of preselected lots of either Liberase (n = 101) or NB1 (n = 96). Utilizing Liberase, significantly more digested tissue and purified islet yield was produced compared to NB1. In contrast, the use of NB1 was associated with significantly higher purity and glucose stimulation index during dynamic perifusion. The expression of proinflammatory markers was almost identical except tissue factor expression, which was higher after utilization of Liberase. No difference was found in the percentage of pancreata fulfilling the criteria for clinical islet transplantation. The results suggest that Liberase is more efficient for pancreas dissociation than collagenase NB1 but seems to be more harmful to exocrine cells and islet tissue.


Journal of General Virology | 2008

An enterovirus strain isolated from diabetic child belongs to a genetic subcluster of echovirus 11, but is also neutralised with monotypic antisera to coxsackievirus A9

Haider Al-Hello; Anja Paananen; Mervi Eskelinen; Petri Ylipaasto; Tapani Hovi; K Salmela; Alexander N. Lukashev; Shubhada Bobegamage; Merja Roivainen

An enterovirus strain (designated D207) isolated from a Slovakian diabetic child and originally serotyped as coxsackievirus A9 (CAV-9) was found to cause rapid cytolysis coinciding with severe functional damage of the surviving cells in primary cultures of human pancreatic islets. This finding prompted us to clone the isolate for full-length genome sequencing and molecular characterization as the prototype strain of CAV-9 is known to cause only minimal damage to insulin-producing beta-cells. Based on capsid-coding sequence comparisons, the isolate turned out to be echovirus 11 (E-11). Phylogenetic analyses demonstrated that E-11/D207 was closely related to a specific subgroup B of E-11 strains known to cause uveitis. To study further antigenic properties of isolate E-11/D207 and uveitis-causing E-11 strains, neutralization experiments were carried out with CAV-9- and E-11-specific antisera. Unlike the prototype strains, the isolate E-11/D207 and uveitis-causing E-11 strains were well neutralized with both CAV-9- and E-11-specific antisera. Attempts to identify recombination of the capsid coding sequences as a reason for double-reactivity using the Simplot analysis failed to reveal major transferred motifs. However, peptide scanning technique was able to identify antigenic regions of capsid proteins of E-11/D207 as well as regions cross-reacting with an antiserum raised to CAV-9. Thus, double specificity of E-11/D207 seems to be a real characteristic shared by the phylogenetically closely related virus strains in the genetic subgroup B of E-11.


Transplantation | 2012

Characteristics of BKV Viremia and Polyomavirus-Associated Nephropathy in Well HLA-Matched Kidney Transplant Recipients Mainly on Low-Dose Cyclosporine: 1001

Ilkka Helanterä; K Salmela; Lauri Kyllönen; A. Räisänen-Sokolowski; E. Auvinen; L. Mannonen; Petri K. Koskinen; Irmeli Lautenschlager

Helanterä I.1, Salmela K.2, Kyllönen L.2, Räisänen-Sokolowski A.3, Auvinen E.4, Mannonen L.4, Koskinen P.1, Lautenschlager I.4 1Helsinki University Central Hospital, Department of Medicine, Division of Nephrology, Helsinki, Finland, 2Helsinki University Central Hospital, Department of Transplant Surgery, Helsinki, Finland, 3Helsinki University Central Hospital, Department of Pathology, Helsinki, Finland, 4Helsinki University Central Hospital, Department of Virology, Helsinki, Finland


Transplantation | 2005

Current status of clinical islet transplantation.

Olle Korsgren; Bo Nilsson; Christian Berne; M Felldin; Aksel Foss; Ragnar Källén; Torgny Lundgren; K Salmela; Annika Tibell; Gunnar Tufveson


Diabetologia | 2005

Global profiling of coxsackievirus- and cytokine-induced gene expression in human pancreatic islets.

Petri Ylipaasto; Burak Kutlu; Suvi Rasilainen; Joanne Rasschaert; K Salmela; Heli Teerijoki; Olle Korsgren; Riitta Lahesmaa; Tapani Hovi; Decio L. Eizirik; Timo Otonkoski; Merja Roivainen


Transplantation Proceedings | 2005

Key Factors for Human Islet Isolation and Clinical Transplantation

Masafumi Goto; Ulrika Johansson; Torsten Eich; T Lundgrem; M Engkvist; M Felldin; Aksel Foss; Ragnar Källén; K Salmela; Annika Tibell; Gunnar Tufveson; Bo Nilsson; Olle Korsgren

Collaboration


Dive into the K Salmela's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Aksel Foss

Oslo University Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Leena Halme

Helsinki University Central Hospital

View shared research outputs
Researchain Logo
Decentralizing Knowledge